For the quarter ending 2025-09-30, QNRX has $6,423,664 in assets. $7,638,284 in debts. $1,830,906 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 1,830,906 | 1,668,492 | ||
| Investments | 3,581,772 | 6,121,830 | ||
| Prepaid expenses and other current assets | 602,652 | 688,933 | ||
| Total current assets | 6,015,330 | 8,479,255 | ||
| Intangible assets, net | 408,334 | 433,334 | ||
| Total assets | 6,423,664 | 8,912,589 | ||
| Accounts payable | 1,860,719 | 873,684 | ||
| Accrued expenses | 2,157,581 | 1,717,564 | ||
| Accrued interest and financing expense | 1,146,251 | 1,146,251 | ||
| Due to officers - short term | 600,000 | 600,000 | ||
| Total current liabilities | 5,764,551 | 4,337,499 | ||
| Due to officers - long term | 1,873,733 | 2,023,733 | ||
| Total liabilities | 7,638,284 | 6,361,232 | ||
| Ordinary shares, no par value per share, 5,000,000,000 and 100,000,000 ordinary shares authorized at september 30, 2025 and december 31, 2024, respectively - 20,585,830 (588,166 ads's) ordinary shares issued and outstanding at september 30, 2025 and 8,948,164 (255,661 ads's) ordinary shares issued and outstanding at december 31, 2024 | 0 | 0 | ||
| Additional paid in capital | 65,407,454 | 65,225,266 | ||
| Accumulated deficit | -66,622,074 | -62,673,909 | ||
| Total shareholders' equity (deficit) | -1,214,620 | 2,551,357 | ||
| Total liabilities and shareholders' equity (deficit) | 6,423,664 | 8,912,589 | ||
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)